Daniel J Crona
Overview
Explore the profile of Daniel J Crona including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
497
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Zhu J, Campagne O, Torrice C, Flynn G, Miller J, Patel T, et al.
Clin Transl Sci
. 2021 Jan;
14(3):908-918.
PMID: 33502111
Tacrolimus is a calcineurin inhibitor used to prevent acute graft versus host disease in adult patients receiving allogeneic hematopoietic stem cell transplantation (HCT). Previous population pharmacokinetic (PK) models have been...
22.
Zhu J, Pasternak A, Crona D
Pharmacogenomics
. 2020 Sep;
21(15):1061-1064.
PMID: 32896220
No abstract available.
23.
Zhu J, Beechinor R, Thompson T, Schorzman A, Zamboni W, Crona D, et al.
Genes Brain Behav
. 2020 May;
20(2):e12666.
PMID: 32383297
Cocaine (COC) is a psychostimulant with a high potential for abuse and addiction. Risk for COC use disorder is driven, in part, by genetic factors. Animal models of addiction-relevant behaviors...
24.
Black R, Williams A, Ratner L, Crona D, Wiltshire T, Weck K, et al.
Pharmacogenomics
. 2020 Apr;
21(7):431-441.
PMID: 32343201
genotyping is used to guide antiplatelet therapy after percutaneous coronary intervention (PCI). This study evaluated the potential impact of and multigene pharmacogenomics (PGx) testing on medications beyond antiplatelet therapy in...
25.
Zhu J, Patel T, Miller J, Torrice C, Aggarwal M, Sketch M, et al.
Int J Mol Sci
. 2020 Feb;
21(3).
PMID: 32013193
Tacrolimus exhibits high inter-patient pharmacokinetics (PK) variability, as well as a narrow therapeutic index, and therefore requires therapeutic drug monitoring. Germline mutations in cytochrome P450 isoforms 4 and 5 genes...
26.
Asquith C, Maffuid K, Laitinen T, Torrice C, Tizzard G, Crona D, et al.
ChemMedChem
. 2019 Aug;
14(19):1693-1700.
PMID: 31424613
Quinoline- and quinazoline-based kinase inhibitors of the epidermal growth factor receptor (EGFR) have been used to target non-small cell lung cancer (NSCLC) and chordomas with varying amounts of success. We...
27.
Asquith C, Fleck N, Torrice C, Crona D, Grundner C, Zuercher W
Bioorg Med Chem Lett
. 2019 Aug;
29(18):2695-2699.
PMID: 31378571
We screened a series of 4-anilinoquinolines and 4-anilinoquinazolines and identified novel inhibitors of Mycobacterium tuberculosis (Mtb). The focused 4-anilinoquinoline/quinazoline scaffold arrays yielded compounds with high potency and the identification of...
28.
Valgus J, Weitzel K, Peterson J, Crona D, Formea C
Am J Health Syst Pharm
. 2019 Jul;
76(8):521-529.
PMID: 31361863
Purpose: This report examines and evaluates pharmacogenomics as an emerging science as it relates to the Practice Advancement Initiative and its predecessor the Pharmacy Practice Model Initiative's consensus statements for...
29.
Moll S, Crona D, Martin K
Res Pract Thromb Haemost
. 2019 Apr;
3(2):152-155.
PMID: 31011697
No abstract available.
30.
Cavallari L, Van Driest S, Prows C, Bishop J, Limdi N, Pratt V, et al.
Genet Med
. 2019 Mar;
21(10):2255-2263.
PMID: 30894703
Purpose: A number of institutions have clinically implemented CYP2D6 genotyping to guide drug prescribing. We compared implementation strategies of early adopters of CYP2D6 testing, barriers faced by both early adopters...